Pear Therapeutics, Inc. Class A Common Stock
PEAR
PEAR was delisted on the 18th of April, 2023.
60 hedge funds and large institutions have $168M invested in Pear Therapeutics, Inc. Class A Common Stock in 2022 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 7 closing their positions.
286% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 7
133% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 6
50% more funds holding
Funds holding: 40 → 60 (+20)
42% more capital invested
Capital invested by funds: $118M → $168M (+$49.7M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.39M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.67M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.17M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.04M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$789K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
5VM
5AM Venture Management
San Francisco,
California
|
-$2.93M |
| 2 |
Millennium Management
New York
|
-$380K |
| 3 |
HF
HRT Financial
New York
|
-$310K |
| 4 |
E
Ergoteles
New York
|
-$111K |
| 5 |
JP Morgan Chase
New York
|
-$93K |
PEAR Hedge Fund Activity: Q3 2022 in Review
60 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) for Q3 2022, worth a combined $168M — up 42% from $118M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new PEAR positions and 7 closed out — a net gain of 20 holders — while 14 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $4.39M. The largest seller was 5AM Venture Management, cutting an estimated $2.93M.
- 60 institutional investors held Pear Therapeutics, Inc. Class A Common Stock (PEAR) as of Q3 2022, up from 40 in Q2 2022.
- Funds reported $168M of Pear Therapeutics, Inc. Class A Common Stock stock for Q3 2022, up 42% quarter-over-quarter.
- 27 funds opened new Pear Therapeutics, Inc. Class A Common Stock positions in Q3 2022 and 7 closed out, a net change of +20 holders.
- The largest Pear Therapeutics, Inc. Class A Common Stock buyer in Q3 2022 was BlackRock, an estimated $4.39M added.
- The largest Pear Therapeutics, Inc. Class A Common Stock seller in Q3 2022 was 5AM Venture Management, an estimated $2.93M sold.
Based on aggregated 13F filings for Q3 2022.